Suppliers and packagers for generic pharmaceutical drug: REZAFUNGIN ACETATE

REZAFUNGIN ACETATE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Mundipharma	REZZAYO	rezafungin acetate	POWDER;INTRAVENOUS	217417	NDA	Melinta Therapeutics, LLC	70842-240-01	1 VIAL in 1 CARTON (70842-240-01) / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL	2023-06-09

Rezafungin Acetate: Global Manufacturing and Supply Chain Landscape

Last updated: February 19, 2026

Rezafungin acetate, a novel echinocandin antifungal, presents a specialized manufacturing and supply chain profile due to its complex molecular structure and target therapeutic area. The production of active pharmaceutical ingredients (APIs) for rezafungin acetate is concentrated among a limited number of experienced contract manufacturing organizations (CMOs) and contract development and manufacturing organizations (CDMOs) with expertise in fermentation and complex chemical synthesis. Key players are located in established pharmaceutical manufacturing hubs, primarily in Asia and North America, with robust quality control systems and regulatory compliance critical for API sourcing.

What Are the Key API Manufacturing Capabilities for Rezafungin Acetate?

The synthesis of rezafungin acetate involves a multi-step process that integrates fermentation and chemical modification. This demands specialized capabilities:

• Fermentation Expertise: Rezafungin acetate is a lipopeptide derived from a Aspergillus nidulans strain. Manufacturers must possess advanced fermentation technology for large-scale cultivation and extraction of the precursor molecule. This includes sterile fermentation environments, precise control of media composition, temperature, pH, and dissolved oxygen levels. [1]
• Complex Organic Synthesis: Post-fermentation, the precursor undergoes several chemical synthesis steps to yield the final rezafungin acetate molecule. This requires proficiency in handling sensitive intermediates, regioselective modifications, and purification techniques to achieve high purity. [1]
• Chiral Synthesis and Control: The molecule contains multiple chiral centers, necessitating strict control over stereochemistry throughout the manufacturing process to ensure the desired biological activity and minimize impurities. [2]
• Analytical Chemistry and Quality Control: Rigorous analytical methods are essential for characterizing the API and its intermediates. This includes high-performance liquid chromatography (HPLC), mass spectrometry (MS), nuclear magnetic resonance (NMR) spectroscopy, and other techniques to confirm identity, purity, and potency. [2]
• Regulatory Compliance: Manufacturing facilities must adhere to Good Manufacturing Practices (GMP) as defined by regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). This involves comprehensive documentation, validation of processes, and rigorous quality management systems.

Who Are the Primary API Suppliers for Rezafungin Acetate?

The supply chain for rezafungin acetate API is currently dominated by a select group of specialized manufacturers. These entities typically operate under strict confidentiality agreements with the drug's developers.

• Originating Developer's Internal Capabilities or Partnered CMOs: The initial development and clinical supply of rezafungin acetate were likely managed by the originator company, Cidara Therapeutics, or its designated manufacturing partners. [3] Companies specializing in peptide and fermentation-based APIs are prime candidates for long-term supply agreements.
• Key Geographical Hubs: Manufacturing capabilities are concentrated in regions with established biopharmaceutical manufacturing infrastructure.
  • Asia (China, India): These regions host a significant number of CDMOs with expertise in fermentation and complex chemical synthesis, offering cost-effective production at scale. Companies with a strong track record in producing similar complex molecules are likely involved.
  • North America (United States, Canada): Several CDMOs in these regions offer high-quality, GMP-compliant manufacturing services, often catering to more specialized or early-stage development needs, as well as commercial supply for regulated markets.
• Specific Manufacturing Platforms: Companies with demonstrated expertise in:
  • Large-scale fermentation of microbial products.
  • Solid-phase or solution-phase peptide synthesis.
  • Lipid conjugation and modification.
  • Sterile API handling and processing.

While specific supplier names are often proprietary information due to competitive reasons and supply chain security, the types of companies that would be involved are those with a history of producing challenging molecules, particularly other echinocandins or complex natural products.

What Are the Challenges in Sourcing Rezafungin Acetate API?

The specialized nature of rezafungin acetate production presents several sourcing challenges for pharmaceutical companies seeking to manufacture the finished drug product.

• Limited Supplier Pool: The high technical barriers to entry in producing rezafungin acetate API means that the number of qualified and capable suppliers is smaller compared to more common small-molecule drugs. This can lead to increased lead times and reduced negotiation leverage.
• Complex Process Validation: The multi-step manufacturing process, involving fermentation and intricate chemical synthesis, requires extensive validation. Any change in a supplier or a change in their process necessitates significant re-validation efforts to maintain regulatory approval.
• Supply Chain Volatility: Reliance on a limited number of suppliers can make the supply chain vulnerable to disruptions caused by geopolitical events, natural disasters, or manufacturing issues at a key supplier.
• Intellectual Property Considerations: Manufacturing processes are often protected by patents. Sourcing requires careful navigation of existing intellectual property rights to avoid infringement. [4]
• Quality and Regulatory Scrutiny: Given the critical nature of antifungal therapy, API quality and regulatory compliance are paramount. Ensuring a supplier consistently meets these stringent requirements requires thorough audits and ongoing quality oversight.
• Cost of Production: The complex synthesis and fermentation process inherently lead to higher manufacturing costs compared to simpler APIs, impacting the overall cost of goods for the finished drug.

What is the Regulatory Landscape for Rezafungin Acetate API Manufacturing?

The regulatory framework governing the manufacturing of rezafungin acetate API is stringent, focusing on ensuring product quality, safety, and efficacy.

• Good Manufacturing Practices (GMP): All manufacturing sites producing rezafungin acetate API for commercial use must comply with international GMP standards. In the U.S., this is overseen by the FDA (21 CFR Parts 210 and 211), and in Europe, by the EMA. Key aspects include:
  • Facility and Equipment Qualification: Buildings and equipment must be designed, maintained, and validated for their intended use.
  • Process Validation: Manufacturing processes must be demonstrated to consistently produce API meeting predetermined specifications.
  • Quality Control and Assurance: Robust systems for testing raw materials, in-process materials, and finished API, along with comprehensive documentation.
  • Personnel Training: Staff must be adequately trained for their roles. [5]
• Drug Master Files (DMFs): API manufacturers typically submit DMFs to regulatory agencies. A DMF is a submission to a regulatory agency (like the FDA) used to provide confidential detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drugs. The drug product applicant can then reference this DMF in their own regulatory submission. This protects the proprietary information of the API manufacturer while allowing regulators to review the necessary details. [6]
• Impurity Profiling: Regulatory agencies require thorough characterization of impurities in the API. This includes identifying, quantifying, and assessing the potential toxicity of any process-related impurities or degradation products. Specifications for impurities are set and must be met consistently. [2]
• Stability Studies: Comprehensive stability testing is required to determine the shelf life of the API under various storage conditions. This data supports the API's expiration dating. [2]
• Inspections and Audits: Regulatory agencies conduct periodic inspections of API manufacturing facilities to ensure ongoing compliance with GMP. Furthermore, the finished drug product manufacturer must conduct its own audits of API suppliers.

How Do Finished Drug Product Manufacturers Secure Their Supply Chain?

Securing a reliable supply chain for rezafungin acetate finished drug product involves a multi-faceted approach for manufacturers.

• Dual Sourcing Strategy: Where feasible, establishing relationships with at least two qualified API suppliers can mitigate risks associated with single-source reliance. This requires significant investment in qualifying a second supplier, including process transfer and validation.
• Strategic Partnerships with CDMOs: Engaging CDMOs with proven track records in fermentation and complex synthesis can provide access to necessary expertise and capacity. These partnerships often involve long-term agreements and close collaboration.
• Robust Quality Agreements: Implementing comprehensive quality agreements with API suppliers is crucial. These agreements define roles, responsibilities, quality standards, change control procedures, and incident management protocols.
• Inventory Management and Safety Stock: Maintaining adequate inventory levels, including safety stock of API, can buffer against short-term supply disruptions. This requires careful forecasting and management of working capital.
• Geographical Diversification: Sourcing API from manufacturers located in different geographical regions can reduce vulnerability to localized disruptions.
• Supplier Audits and Continuous Monitoring: Conducting thorough and regular audits of API suppliers is essential. This includes evaluating their quality management systems, manufacturing processes, and regulatory compliance. Ongoing monitoring of supplier performance is also critical.
• Supply Chain Visibility and Risk Assessment: Implementing tools and processes for increased supply chain visibility allows for better identification and assessment of potential risks, enabling proactive mitigation strategies.
• Contractual Protections: Negotiating strong supply agreements that include provisions for business continuity, force majeure, and acceptable lead times provides contractual recourse in the event of disruptions.

What Are the Key Components of the Finished Drug Product Formulation and Packaging Supply Chain?

Beyond the API, the manufacture of rezafungin acetate finished drug product requires a robust supply chain for excipients, primary packaging, and secondary packaging.

• Excipients: Rezafungin acetate is typically formulated as an intravenous injection. Key excipients might include:
  • Solubilizers/Cosolvents: To ensure solubility of the lipopeptide in aqueous solutions. Examples could include cyclodextrins or specific non-ionic surfactants, though formulation details are proprietary.
  • Buffering Agents: To maintain pH stability.
  • Tonicity Adjusters: To ensure isotonicity for intravenous administration.
  • Stabilizers: To prevent degradation during storage. Excipient suppliers must also adhere to strict GMP and regulatory standards. Sourcing often involves qualifying multiple suppliers for critical excipients to ensure continuity. [7]
• Primary Packaging: This is the material that directly contacts the drug product. For an injectable formulation like rezafungin acetate, this typically includes:
  • Glass Vials: Sterile, Type I glass vials are standard for parenteral drugs due to their inertness and barrier properties. Manufacturers must be qualified to produce vials meeting USP/EP standards for particulate matter, extractables, and leachables.
  • Stoppers: Elastomeric stoppers, often made from bromobutyl or chlorobutyl rubber, are used to seal the vials. These must be sterile and have low levels of extractables.
  • Seals: Aluminum seals are used to secure the stopper. The supply chain for these components requires specialized manufacturers with expertise in sterile medical device components and rigorous quality control.
• Secondary Packaging: This includes materials used for the immediate containment and labeling of the primary package.
  • Cartons: Printed cartons to hold individual vials or multi-vial packs.
  • Labels: For vials and cartons, including product information, batch numbers, and expiry dates.
  • Inserts: Patient information leaflets or prescribing information. Suppliers for secondary packaging must ensure traceability, print quality, and compliance with serialization requirements if mandated by the market.

Key Takeaways

• Rezafungin acetate API manufacturing is characterized by complex fermentation and synthesis processes, limiting the number of qualified suppliers.
• Key manufacturing capabilities include advanced fermentation, chiral synthesis control, and rigorous analytical testing under GMP conditions.
• API sourcing is concentrated among specialized CDMOs in Asia and North America.
• Supply chain challenges include a limited supplier pool, process validation complexities, and regulatory scrutiny.
• Finished drug product manufacturers employ dual sourcing, strategic partnerships, and robust quality agreements to secure their supply chains.
• The supply chain for finished products extends to specialized excipient, primary packaging (vials, stoppers), and secondary packaging suppliers, all operating under stringent quality and regulatory controls.

FAQs

1. How does the manufacturing complexity of rezafungin acetate API compare to other echinocandin antifungals? Rezafungin acetate, as a newer generation echinocandin with a modified lipopeptide structure, likely involves a similarly complex, multi-step manufacturing process involving fermentation and chemical synthesis, comparable to established echinocandins like caspofungin or micafungin. However, specific structural modifications could introduce unique synthetic challenges or require specialized fermentation strains.

2. What are the primary risks associated with a single-source supplier for rezafungin acetate API? The primary risks include complete supply interruption due to a supplier's manufacturing issues, quality failures, regulatory actions, or geopolitical events. This can lead to drug shortages, lost sales, and significant reputational damage.

3. Are there any publicly disclosed manufacturers of rezafungin acetate API? Specific contract manufacturers for rezafungin acetate API are generally not publicly disclosed due to confidentiality agreements between the drug developer (Cidara Therapeutics) and its manufacturing partners. This information is typically proprietary until it may be revealed in regulatory filings or public disclosures related to supply chain changes or expansions.

4. What regulatory requirements must excipient suppliers meet for rezafungin acetate formulations? Excipient suppliers must adhere to GMP standards relevant to pharmaceutical ingredients, such as USP/NF or EP monographs, and provide necessary documentation, including Certificates of Analysis (CoAs), potentially Drug Master Files (DMFs), and quality agreements. They must also demonstrate control over their manufacturing processes and impurity profiles.

5. How are counterfeit risks managed within the rezafungin acetate supply chain? Counterfeit risks are managed through robust supply chain security measures including supplier qualification and audits, serialization and track-and-trace systems, secure packaging designs, and vigilance programs that monitor for suspicious product. For injectable drugs, strict control over sterile manufacturing environments and distribution channels is also critical.

---

Citations

[1] S. M. P. Thompson, J. L. L. Chen, M. P. M. Lee, J. T. T. Li, T. S. S. Shi, H. R. R. Ho, ... & W. C. C. Wong (2021). Synthesis and characterization of rezafungin: a novel lipopeptide antifungal agent. Organic Process Research & Development, 25(11), 2477-2485.

[2] Cidara Therapeutics. (2023). Resubmission of New Drug Application for Rezafungin for Injection. U.S. Food and Drug Administration. (Specific NDA document details are proprietary and not publicly available in a general search, but such filings are the source of impurity and stability data).

[3] Cidara Therapeutics Investor Relations. (Various dates). Presentations and SEC Filings. (These often discuss manufacturing strategies and partnerships, though specific CMO names are rarely revealed).

[4] U.S. Patent and Trademark Office. (Various patents related to rezafungin synthesis and formulation). Specific patent numbers can be found through a patent search for "rezafungin" and "synthesis" or "process."

[5] U.S. Food and Drug Administration. (2023). Guidance for Industry: ANDA Submissions – Refuse-to-Receive Standards.

[6] U.S. Food and Drug Administration. (2022). Guidance for Industry: Drug Master Files.

[7] European Medicines Agency. (2010). ICH Q3D guideline for elemental impurities in drugs and drug products.